Foresee Pharmaceuticals Advances CPP Treatment as First Clinical Trial Recommended for Continuation Foresee Pharmaceuticals' Casppian Phase 3 study receives a positive recommendation to continue, showcasing innovative treatment for Central Precocious Puberty.

Foresee Pharmaceuticals Advances CPP Treatment as First Clinical Trial Recommended for Continuation #Taiwan #Taipei #Foresee_Pharmaceuticals #CPP_Treatment #Casppian_Study

Foresee Pharmaceuticals Expands Reach with New Licensing Deal for MMP-12 Inhibitors Foresee Pharmaceuticals signs a global licensing agreement with Primevera Therapeutics for MMP-12 inhibitors, emphasizing growth and financial stability.

Foresee Pharmaceuticals Expands Reach with New Licensing Deal for MMP-12 Inhibitors #Taipei #USA #Foresee_Pharmaceuticals #Primevera_Therapeutics #MMP-12_Inhibitors

Foresee Pharmaceuticals Enters Global Licensing Agreement with Primevera for MMP-12 Inhibitors Foresee Pharmaceuticals announces its exclusive global licensing deal with Primevera Therapeutics for MMP-12 inhibitors, enhancing its financial stability and profitability.

Foresee Pharmaceuticals Enters Global Licensing Agreement with Primevera for MMP-12 Inhibitors #Taiwan #Taipei #Foresee_Pharmaceuticals #Primevera_Therapeutics #MMP-12_Inhibitors

Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment Foresee Pharmaceuticals announces remarkable results from their Phase 3 Casppian study, showcasing impressive LH suppression in children with Central Precocious Puberty, with a six-month dosing schedule.

Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #leuprolide_mesylate #Central_Precocious_Puberty

Foresee Pharmaceuticals' CAMCEVI ETM Receives FDA Approval for Advanced Prostate Cancer Treatment Foresee Pharmaceuticals has announced FDA approval for CAMCEVI ETM, a new treatment for advanced prostate cancer, advancing patient care significantly.

Foresee Pharmaceuticals' CAMCEVI ETM Receives FDA Approval for Advanced Prostate Cancer Treatment #Taipei #United_States #FDA_Approval #Foresee_Pharmaceuticals #CAMCEVI

Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment Foresee Pharmaceuticals has completed the enrollment for its Phase 3 Casppian trial, examining leuprolide mesylate's safety and efficacy in treating Central Precocious Puberty.

Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #Casppian_trial #leuprolide_mesylate

Foresee Pharmaceuticals Commences Groundbreaking Phase 2 Study for Mirivadelgat in Treating Pulmonary Hypertension-Associated ILD Foresee Pharmaceuticals has initiated the Phase 2 WINDWARD study for Mirivadelgat, a promising treatment for patients suffering from PH-ILD. This innovative trial aims to evaluate the drug's safety and effectiveness.

Foresee Pharmaceuticals Commences Groundbreaking Phase 2 Study for Mirivadelgat in Treating Pulmonary Hypertension-Associated ILD #Taipei #United_States #Foresee_Pharmaceuticals #Mirivadelgat #PH-ILD

Foresee Pharmaceuticals to Unveil New Asthma Treatment Research at 2025 ATS Conference Foresee Pharmaceuticals is set to present groundbreaking research on a new asthma treatment at the 2025 ATS Conference, aiming to tackle unmet needs in asthma management.

Foresee Pharmaceuticals to Unveil New Asthma Treatment Research at 2025 ATS Conference #United_States #San_Francisco #Foresee_Pharmaceuticals #MMP-12 #Linvemastat

Foresee Pharmaceuticals Achieves Another Milestone in Casppian Study towards CPP Treatment Foresee Pharmaceuticals has received a positive recommendation from the Data and Safety Monitoring Board for their Casppian study, enhancing treatment options for children suffering from central precocious puberty.

Foresee Pharmaceuticals Achieves Another Milestone in Casppian Study towards CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #CAMCEVI #CPP_Treatment

Foresee Pharmaceuticals' Abstract Set for Presentation at ASCO GU Symposium 2025 Foresee Pharmaceuticals announces the acceptance of its abstract for the ASCO-GU Symposium 2025, highlighting advancements in prostate cancer treatment.

Foresee Pharmaceuticals' Abstract Set for Presentation at ASCO GU Symposium 2025 #USA #San_Francisco #Foresee_Pharmaceuticals #Prostate_Cancer #ASCO_GU

Foresee Pharmaceuticals Sets PDUFA Goal Date for CAMCEVI's 3-Month Injectable Formula Foresee Pharmaceuticals announces FDA's PDUFA goal date for CAMCEVI 3-month version as August 29, 2025, promising new treatment options for prostate cancer.

Foresee Pharmaceuticals Sets PDUFA Goal Date for CAMCEVI's 3-Month Injectable Formula #Taiwan #Taipei #Foresee_Pharmaceuticals #CAMCEVI #PDUFA

Foresee Pharmaceuticals Secures $42.1 Million through Successful Public Offering to Propel Drug Development Foresee Pharmaceuticals successfully raised $42.1 million in a public offering, aiming to bolster advancements in treatments for serious medical conditions.

Foresee Pharmaceuticals Secures $42.1 Million through Successful Public Offering to Propel Drug Development #Taiwan #Taipei #Foresee_Pharmaceuticals #FP-014 #CAMCEVI